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Abstract
Aberrant miRNA expression has been previously established in breast cancer and has clinical relevance. However, no studies
so far have defined miRNAs deregulated in hereditary breast tumors. In this study we investigated the role of miRNAs in
hereditary breast tumors comparing with normal breast tissue. Global miRNA expression profiling using Exiqon microarrays
was performed on 22 hereditary breast tumors and 15 non-tumoral breast tissues. We identified 19 miRNAs differentially
expressed, most of them down-regulated in tumors. An important proportion of deregulated miRNAs in hereditary tumors
were previously identified commonly deregulated in sporadic breast tumors. Under-expression of these miRNAs was
validated by qRT-PCR in additional 18 sporadic breast tumors and their normal breast tissue counterparts. Pathway
enrichment analysis revealed that deregulated miRNAs collectively targeted a number of genes belonging to signaling
pathways such as MAPK, ErbB, mTOR, and those regulating cell motility or adhesion. In silico prediction detected KRAS
oncogene as target of several deregulated miRNAs. In particular, we experimentally validated KRAS as a miR-30c target.
Luciferase assays confirmed that miR-30c binds the 39UTR of KRAS transcripts and expression of pre-miR-30c down-
regulated KRAS mRNA and protein. Furthermore, miR-30c overexpression inhibited proliferation of breast cancer cells. Our
results identify miRNAs associated to hereditary breast cancer, as well as miRNAs commonly miss-expressed in hereditary
and sporadic tumors, suggesting common underlying mechanisms of tumor progression. In addition, we provide evidence
that KRAS is a target of miR-30c, and that this miRNA suppresses breast cancer cell growth potentially through inhibition of
KRAS signaling.
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Introduction
Breast cancer is the most common malignancy among women
in developed countries. The majority of breast cancers are
sporadic, while familial breast cancer comprises 5–10% of all
breast cancers. Germline mutations in the currently known high
risk-breast cancer genes (such as BRCA1/2) are common in
familial breast cancer, but they can explain, at best, 20–25% of
the overall excess familial risk. [1]. Still, the large majority of
breast cancer cases that arise in families with strong familial
aggregation are not explained by mutations in any know breast
cancer susceptibility gene, and are designated as BRCAX-type
tumors [2].
In the past decade, gene expression profiling by microarray
analysis has lead to great advances in classification of human
breast tumors, and the identification of five reproducible
molecular subtypes of breast cancer, that have distinct biological
features, clinical outcomes, and responses to chemotherapy [3].
On the other hand, there have been only a handful of studies
focused on familial breast cancer, due to difficulties in collecting
the tumor material, demonstrating that BRCA1/2-mutated breast
tumors could be distinguished from sporadic ones based on their
gene expression signatures [4].
Recently, microRNA (miRNA) expression profiling calls a great
attention to define various types of cancers [5,6]. miRNAs are an
abundant class of small ,22 nt long single-stranded non-coding
RNA molecules acting as negative regulators at post-transcrip-
tional level by binding the 39 untranslated regions (39UTRs) of
their mRNA-targets [7]. miRNAs are involved in crucial biological
processes including development, differentiation, apoptosis and
proliferation [6]. Notably, miRNA deregulation has been exten-
sively implicated in cancer pathogenesis in various tumor types
[8,9]. The observed effects of miRNA mis-expression on tumor
initiation, maintenance or metastasis can be explained by the
mRNA targets and pathways they regulate, which include known
tumor suppressors and oncogenes [10]. Specifically, in breast
cancer, various studies have identified mis-expressed miRNAs in
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expression seem to define, similarly to what has been found by
expression profiling of coding genes, different histological (lobular/
ductal, ER+/ER2) [11,12] and molecular (luminal A, luminal B,
basal-like, HER2+) subtypes described so far [13]. In addition,
integration of miRNA and mRNA data of a set of breast cancer
samples allowed the association of miRNAs to relevant cellular
processes, such as proliferation, cell cycle, immune response or cell
adhesion, as well as with molecular characteristics of tumors like
TP53 mutations [14].
Still, very little is known about the role of miRNAs in familial
breast cancer. The identification of target genes and pathways
regulated by miRNAs would be critical to understand their
function in tumor development. In this study we sought to
establish miRNA expression profiles using microarray technology
of familial breast cancer tumors and comparing with normal
breast tissues. Interestingly, KRAS has been identified as a target
oncogene for down-regulated miRNAs. Direct regulation of
KRAS by miR-30c and growth inhibition by this miRNA was
experimentally demonstrated. The identification of miRNAs
deregulated in familial breast tumors could provide a better
understanding of the biology of familial breast cancer and could
indicate novel targets for therapy.
Results
miRNA Expression Profiling in Primary Familial Breast
Tumors and Normal Breast Tissue
In order to establish the miRNA profile of hereditary breast
tumors, we used LNA based microRNA microarrays. After initial
preprocessing we had data from 1276 hsa-miRNAs (831 hsa-miR
and 434 hsa-miRPlus). A filter procedure to eliminate genes with
low expression variation across the experiments (SD,0.3) and
with uniformly low expression, reduced the number of miRNAs to
a total of 327 hsa-miRNAs (198 hsa-miR and 118 miRPlus). In an
effort to detect significant differences in miRNA expression
between normal breast tissue and hereditary breast tumors, we
performed a differential expression analysis. We identified 19
miRNA significantly differentially expressed (FDR,0.05) between
normal breast tissue and familial tumoral samples (Figure 1).
Almost all differentially expressed miRNAs were found to be
down-regulated in tumor tissues, with the exception of miR-21
and miR-300 that were up-regulated in breast tumors compared to
normal breast tissue (Table 1). Down-regulation of selected
miRNAs was validated by qRT-PCR in an independent set of
tumors (Figure S1).
Expression of these 19 differentially expressed miRNAs in
normal Human Mammary Epithelial Cells (HMEC) was similar to
the expression in normal breast tissue although some differences
also exist for specific miRNAs. HMEC cells represent normal
proliferating cells and normal tissue represent preferentially non
proliferating cells, therefore, down regulation of some miRNAs,
such as miR-99a, miR-101 or miR-145 (Figure 1), might be
related to both normal and tumoral proliferation. However, down-
regulation of other miRNAs, miR-205, miR-125a/b, miR-100 or
miR-30c, might have a role in more specific tumoral processes.
miRNAs Commonly Deregulated in Familial and Sporadic
Breast Cancer
Interestingly, several miRNAs that we found to be deregulated
in familial breast cancer were previously described to be
deregulated in sporadic breast tumors. Thus, 11 of the 19
miRNAs (miR-10b, -100, -101, -125a, -125b, 130a, -143, -145, -
21, -205, and -30c) were previously identified in two key studies as
being miss-regulated in sporadic breast tumors in comparison to
normal tissue [11,12], suggesting that these miRNAs may play
a general role in breast carcinogenesis (Figure 2). Deregulation of
some of these miRNAs in sporadic tumors was also confirmed by
qRT-PCR analysis in an independent set of 18 sporadic breast
tumors (Figure S1).
Pathway Enrichment Analysis
Given the fact that a single miRNA can target a large number of
mRNA transcripts, miss-expression of a set of miRNAs could have
significant effect on cellular function by affecting multiple signaling
pathways. To assess the potential impact of deregulated miRNA in
hereditary breast tumors on biological processes and pathways, we
used Diana miRPath web-based computational tool for biological
interpretation of miRNA profiling data using over-representation
analysis of biological processes and signaling pathways that are
targeted collectively by co-expressed miRNAs. KEGG pathway
enrichment analysis has revealed that the set of differentially
expressed miRNAs between normal tissue and hereditary breast
tumors, targets multiple effectors of pathways involved in
ubiquitilation, cell proliferation and migration. Full list of path-
ways that have significantly overrepresented genes (p,0.05)
collectively targeted by the set of 19 differentially expressed
miRNAs is shown in Table 2. Observed down regulation of
miRNAs in tumors regulating expression of these genes may result
in abnormally activated pathways leading to increased pro-
liferation and/or migration abilities.
We focused on the MAPK signaling pathway since a large
number of genes within this pathway were found to be commonly
targeted by 8 out of 19 deregulated miRNAs in our study
suggesting that these miRNAs might cooperate to affect gene
expression and consequentially activation or repression of
signaling pathways (Table 2). Interestingly, miR-30c has potential
binding sites on 20 different target genes involved in MAPK
pathway (Table S1). This miRNA potentially target important
mediators of MAPK signaling, such as KRAS, RASA1, MAP3K1
and MAPK8. Furthermore, KRAS gene has been previously
validated as a target of several miRNAs, including let-7, miR-143
and miR-96 [15,16,17]. Now, we investigated whether miR-30c
could be regulating KRAS expression in hereditary breast tumors.
Thus, we confirmed by pRT-PCR that miR-30c had decreased
expression in both hereditary and sporadic breast tumors
comparing to normal samples (Figure 3). In addition, the other
KRAS regulating miRNAs, let-7 and miRNA-143 were previously
found to be significantly down-regulated in breast tumors [15,16],
while miR-96 regulated KRAS in pancreatic tumors [17].
Although mutations in KRAS are infrequent in breast tumors,
activation of KRAS pathway in breast cancer have been
frequently found. All these data suggests that deregulation of
miRNAs would be a mechanism to explain KRAS overexpression
in breast tumors. The role of miR-143 and miR-145 in regulating
KRAS expression was already described, however it was never
described miR-30c targeting KRAS.
miR-30c Regulates KRAS Expression
We explored the role of miR-30c in regulation of KRAS
expression. A negative correlation between miR-30c expression
and KRAS protein level was observed in two breast cancer cell
lines (Figure 4). In addition, several bioinformatic target prediction
algorithms (DIANA microT4.0, TargetScan, PITA, PicTar,
miRANDA) indicated existence of a broadly conserved putative
binding site for miR-30c in the 39UTR of the KRAS gene
(Figure 5A). To test the hypothesis that KRAS is a bona fide target
of miR-30c, we constructed a reporter plasmid harboring 300 pb
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binding site downstream of the luciferase coding region. MDA-
MB-436 cells were co-transfected with luciferase reporter and pre-
miR-30c or scramble control. As a result, pre-miR-30c transfected
cells showed a marked reduction (52%) of luciferase activity
compared to scramble control, confirming the interaction between
Figure 1. Differentially expressed miRNAs between normal breast tissue and hereditary breast tumors. Heat map of the expression of
the 19 miRNAs differentially expressed between normal samples and tumors, overexpression in red, lower expression in green. Expression of these
miRNAs in Human Mammary Epithelial Cells (HMEC) cells is also represented.
doi:10.1371/journal.pone.0038847.g001
Table 1. miRNAs differentially expressed between normal breast and familial tumor tissue.
miRNA Chromosomal location
Median Normal
Breast
Median Tumor
Tissue Fold change
Unadjusted p
value FDR
1
hsa-miR-205 1q32.2 9.9 7.4 5.9 Q 3.00E207 7.82E205
hsa-miR-125b 11q24.1/21q11.2 11.4 8.9 5.8 Q 6.00E207 7.82E205
hsa-miR-99a 21q11.2 7.4 6.3 2.2 Q 1.30E206 0.0001
hsa-miR-100 11q24.1 7.6 6.4 2.2 Q 2.00E206 0.0001
hsa-miR-145 5q32233 7.3 6.4 1.8 Q 4.95E205 0.0024
hsa-miR-195 17p13 9.1 7.4 3.4 Q 0.000152 0.0062
hsa-miR-10b 2q31 7.6 6.8 1.7 Q 0.00024 0.0084
hsa-miR-320c 18q11.2 7.6 6.9 1.6 Q 0.000412 0.0127
hsa-miR-320d 13q14.11/Xq27.1 7.4 6.7 1.6 Q 0.000512 0.0140
hsa-miR-101 1p31.3 7.4 6.4 2.0 Q 0.000787 0.0185
hsa-miR-130a 11q12 7.5 6.8 1.6 Q 0.000887 0.0185
hsa-miR-320b 1p13.1/1q42.11 8.1 7.3 1.8 Q 0.000938 0.0185
hsa-miR-125a-5p 19q13.4 8.8 8.1 1.6 Q 0.000976 0.0185
hsa-miR-335 7q32.2 7.1 6.5 1.4 Q 0.001195 0.0210
hsa-miR-320a 8p21.3 8.1 7.3 1.8 Q 0.001669 0.0257
hsa-miR-143 5q32233 9.7 8.2 2.8 Q 0.002078 0.0301
hsa-miR-21 17q23.1 9.1 10.1 2.0 q 0.003822 0.0495
hsa-miR-30c 6q13 8.4 7.8 1.5 Q 0.004283 0.0504
hsa-miR-300 14q32.31 7.1 8.0 2.0 q 0.004306 0.0504
1FDR: False discovery rate adjusted p value.
doi:10.1371/journal.pone.0038847.t001
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e38847Figure 2. Shared differentially expressed miRNAs in sporadic breast tumors and hereditary tumors. Venn diagrams representing
commonly deregulated miRNAs in two different studies carried out in sporadic breast cancer samples [11,12] and in the present study on hereditary
breast tumors. Regardless of the genetic background or histopathological features of the tumors, there are miRNAs consistently altered in breast
tumor samples.
doi:10.1371/journal.pone.0038847.g002
Table 2. Significantly enriched signaling pathways associated to the differentially expressed. miRNAs.
KEGG Pathway
Nu of miRNA
Target Genes -LN(p-value) Gene Names
Ubiquitin mediated proteolysis 20 17.18 UBE2D1, SOCS1, UBE2D2, UBE3C, UBE1, MAP3K1, BIRC6, UBE2J1,
UBE2I, SMURF1, UBE2W, CBL, BTRC, WWP1, CUL2, SOCS3, CBLB,
NEDD4L, NEDD4, ITCH
Axon guidance 17 11.88 SRGAP3, PLXNA2, GNAI2, DPYSL2, ITGB1, UNC5C, EFNA3, SEMA4D,
EPHB2, SEMA6D, KRAS, CFL2, NRP1, PPP3CA, RASA1, SEMA3A, NFAT5
Insulin signaling pathway 16 7.96 PPARGC1A, SOCS1, MAPK8, TSC1, PDPK1, KRAS, CBL, FRAP1, CRKL,
SORBS1, SOS1, FOXO1, SOCS3, CBLB, PIK3CD, AKT3
O-Glycan biosynthesis 6 7.23 GALNT2, GALNT7, GALNT1, GALNT3, GCNT1, B4GALT5
mTOR signaling pathway 7 5.31 TSC1, PDPK1, FRAP1, ENSG00000164327, RPS6KA3, PIK3CD, AKT3
ErbB signaling pathway 10 4.74 MAPK8, NRG3, KRAS, CBL, FRAP1, CRKL, SOS1, CBLB, PIK3CD, AKT3
Glycan structures - biosynthesis 1 12 4.35 GALNT2, GALNT7, GALNT1, GALNT3, CHST2, STT3B, CHST1, GCNT1,
EXTL2, B4GALT5, MAN1A2, XYLT1
MAPK signaling pathway 20 3.84 MAP4K4, MAPK8, MAP3K1, KRAS, MEF2C, BDNF, CRKL, TAOK1, STK4,
SOS1, FGFR1, RPS6KA5, FGF2, RAP1B, PPP3CA, NF1, RASA1, MAP3K12,
RPS6KA3, AKT3
Regulation of actin cytoskeleton 17 3.61 ITGB1, WASL, ARHGEF6, KRAS, PIP4K2B, CRKL, CFL2, PIP4K2A, ITGA6,
SOS1, FGFR1, FGF2, ITGB3, GNA13, ACTC1, PIK3CD, PFN2
Adherents junction 8 3.55 IGF1R, SNAI1, WASL, SMAD2, SORBS1, FGFR1, SSX2IP, PVRL1
Focal adhesion 16 3.54 BCL2, MAPK8, ITGB1, IGF1R, PDPK1, CRKL, ITGA6, SOS1, PTEN,PTENP1,
RAP1B, ITGB3, ARHGAP5, CCND2, PIK3CD, AKT3, CCND1
T cell receptor signaling pathway 9 3.2 KRAS, CBL, SOS1, PPP3CA, CBLB, PDCD1, NFAT5, PIK3CD, AKT3
doi:10.1371/journal.pone.0038847.t002
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checked whether miR-30c could affect KRAS mRNA stability by
performing qRT-PCR analysis in MDA-MB-436 cells transiently
transfected with either pre-miR-30c or scramble control. Indeed,
we observed a sharp decrease in KRAS mRNA levels upon
transfections with pre-miR-30c (Figure 5C).
In addition, pre-miR-30c or pre-miR- control were transfected
into MDA-MB-436 cells, and we confirmed a reduction of about
44% of KRAS protein level in MDA-MB-436 cells over-expressing
miR-30c, in comparison to control (Figure 5D).
miR-30c Affects Proliferation of Breast Cancer Cells
To gain more insight into the biological effects of miR-30c on
breast tumorigenesis and given that KRAS plays a role in
regulation of cell proliferation, MDA-MB-436 cells, which pre-
viously showed elevated levels of KRAS protein, were transfected
with pre-miR-30c or scramble and analyzed for cell growth. As
shown in Figure 5E, ectopic expression of miR-30c resulted in
reduced proliferation in comparison to scramble control trans-
fected cells. Therefore, modulation of KRAS protein level by miR-
30c may explain at least in part, why down-regulation of miR-30c
can promote proliferation and contribute to tumorigenesis.
Discussion
miRNA profiling studies in various tumor types have demon-
strated a widespread miRNA deregulation, providing for new
insights in tumor biology, improved classification and opening new
avenues for development of novel targeted therapies in cancer. In
this study we performed miRNA expression profiling in familial
breast tumors and normal breast tissue in order to uncover
deregulated miRNAs. The normal breast tissue series was
obtained from healthy individuals, both from BRCA1/2- mutation
carriers belonging to high risk families, and from mutation-free
individuals undergoing breast reduction surgery. This has enabled
us to pinpoint miRNAs important for tumorigenesis, by removing
the bias induced through effects of BRCA1/2 mutation on
miRNA expression. We have defined down-regulation for 17
miRNAs and up-regulation of miR-21 and miR-300 in familial
breast tumors when comparing to normal breast tissue.
A high proportion of deregulated miRNAs in hereditary tumors
were commonly found in previous studies with sporadic breast
tumors, suggesting that there are miRNAs that likely regulate
important oncogenes involved in both familial and sporadic
tumors, irrespective of their genetic background. It was expected
that comparing tumor samples with normal tissue, which is
characterized by quiescent cells, would uncover miRNAs that may
be mainly involved in proliferation. Expression analysis of the 19
differentially expressed miRNAs in HMEC cells, which represent
normal proliferating cells, have allowed finding some miRNAs
overexpressed in normal tissues that were not overexpressed in
normal HMEC cells, such as miR-99a, miR-101 or miR-145,
which could have a role in the control of proliferation processes in
general. Other miRNAs expressed by both HMEC and normal
breast and down-regulated in tumors tissue may be involved in
other signaling pathways related to tumoral behavior.
Moreover, the pathway enrichment analysis suggested that co-
expressed miRNAs seem to collectively target a broad range of
signaling pathways related to proliferation and cell migration/
motility. Altered cell signaling has long been recognized as
a mechanism employed by cells in the development and pro-
gression of cancer [18]. Importantly, 20 genes within MAPK
signaling pathway were significantly associated with our set of
deregulated miRNAs, suggesting that the inhibition of these
miRNAs would result in a concomitant activation of MAPK
signaling.
In breast cancer, MAPKs play a key role in transducing growth
signals from the extracellular environment [19,20]. The activation
of the KRAS/MAPK pathway generates a plethora of responses
in breast cancer tumors and cell lines, affecting cell growth,
Figure 3. Validation of miR-30c expression by qRT-PCR in
hereditary and sporadic tumors. Expression levels of miR-30c in an
independent set of 12 familial (FamBC) and 8 sporadic tumors (SpoBC)
comparing to normal breast tissue expression. Differences were
estimated by t-test and p values are shown for each comparison.
doi:10.1371/journal.pone.0038847.g003
Figure 4. Correlation of expression of miR-30c and KRAS in two
breast cancer cell lines. Inverse correlation between the expression
level of miR-30 determine by qRT-PCR (A) and detection of KRAS
protein in MCF7 and MDA-MB-436 cells (B).
doi:10.1371/journal.pone.0038847.g004
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cancer development, up-regulation of the KRAS/MAPK signal-
ing can occur through multiple facets, and it has been shown to be
increased in many breast cancer samples either by over-expression
of growth-factor-receptor tyrosine kinases primarily HER2/ErbB-
2, EGFR, and IGFR or by activating mutations [22,23,24,25].
Although KRAS is frequently mutated in human cancers in-
cluding pancreatic, colorectal and lung cancers, KRAS mutations
are extremely rare in breast cancer [26,27]. However wild-type
KRAS is significantly activated in breast cancers that over-express
EGFR and ErbB2 [28]. Additionally many investigators have
reported over-expression of the KRAS-encoded p21 proteins in
breast malignancies in comparison to normal breast tissue [29,30]
although the role of this over-expression in breast carcinogenesis
has not been determined.
Interestingly, KRAS was found to be a target of multiple
miRNAs found to be down-regulated in breast tumors. The let-7
family of miRNAs has been shown to regulate multiple oncogenes,
including KRAS and c-MYC [16], and miR-143/145 are involved
in feed-forward mechanism that potentiates Ras signaling through
down-regulation of KRAS and Ras-responsive element-binding
protein (RREB1), which represses the miR-143/145 promoter
[31]. Here we have identified a novel broadly conserved miRNA,
miR-30c, as a direct negative regulator of KRAS expression.
Interestingly, miR-30 and let-7 were reported to be markedly
reduced in breast tumor-initiating cells and contribute to their self-
renewal capacity and undifferentiated state, and ectopic expression
of these miRNAs in breast tumor-initiating cell xenografts
decreases their tumorigenic and metastatic potential [32].
Furthermore, it has been shown recently that higher expression
of miR-30c was significantly associated to benefit of tamoxifen
treatment and with longer progression-free survival [33]. Alto-
gether, decreased expression of these miRNAs may release the
negative regulation of KRAS. Interestingly, our results showed
Figure 5. miR-30c effects on KRAS expression and cell proliferation. (A) Schematic representation of miR-30c binding site within the KRAS
39UTR region. (B) Luciferase activity of a reporter construct carrying the KRAS 39UTR downstream of the luciferase gene. The construct was co-
transfected with pre-miR-30c or scramble control in MDA-MB-436 cells. (C) KRAS expression at transcription level. Significant reduced level of KRAS
mRNA expression was detected by qRT-PCR after pre-miR-30c transfection, comparing with scramble control. (D) Regulation of KRAS protein level by
miR-30c. MDA-MB-436 cells were transfected with pre-miR-30c or pre-miR-scramble oligonucleotides. After 48 hours KRAS protein was evaluated by
western blot. GAPDH was used as loading control. The signal in each line was quantified and the ratio of KRAS to GAPDH was determined. (E) Effect of
miR-30c expression on proliferation of MDA-MB-436 cells. MTT cell viability assay was performed at 48, 72, 96, 120 or 144 hours after transfection of
MDA-MB-436 cells with pre-miR-30c or pre-miR-scramble oligonucleotides.
doi:10.1371/journal.pone.0038847.g005
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and miR-145) had significantly reduced co-expression in tumors
and then these miRNAs may act together in the regulation of
KRAS oncogene.
Signal transduction pathways integrate signals from extracellu-
lar stimuli including mitogens, growth factors, hormones and
environmental stresses- signals required for tumorigenesis. miRNA
deregulation results in the complex modulation of multiple targets
belonging to multiple pathways. Commonly deregulated miRNAs
in both familial and sporadic breast cancer suggest that commonly
altered pathways could be important for tumor progression. Here,
we have demonstrated that KRAS inhibition through direct
regulation by miR-30c leads to reduced proliferation in breast
cancer cells. Similarly, other studies have identified KRAS as
a target of several miRNAs down-regulated in tumors (let-7, miR-
96 and miR-143), that also have an effect on cancer cell
proliferation and tumor invasiveness [15,16,17]. Therefore, co-
ordinated down-regulation of miRNAs found in breast tumors
would be not only affecting KRAS oncogene expression but also
may be targeting other genes of the KRAS/MAPK signaling
pathway to cooperatively activate tumorigenic downstream
signals.
In general a strong similarity between deregulated miRNAs was
found in hereditary and sporadic breast cancer when compared to
normal breast tissue. However, in order to get miRNAs associated
with BRCA1 and BRCA2 mutated tumors, a higher number of
BRCA1/2 mutated tumors would be needed. In this regard, one
study found very similar miRNA expression profiles in high grade
serous ovarian carcinomas with or without BRCA1/2 mutations
[34]. More studies are guaranteed to determine the role of miRNA
more related to familial breast tumors and those specifically
associated to the BRCA1 and BRCA2 mutated tumors.
In summary, our data defined a deregulated set of miRNAs in
hereditary breast tumors, many of them commonly deregulated in
sporadic breast cancer. These miRNAs mostly showed significant
reduced expression in tumors comparing to normal breast tissue.
One of these miRNAs, miR-30c, potentially contributes to breast
malignancy formation through release of KRAS suppression
suggesting that this miRNA, and likely other miRNAs also
targeting KRAS/MAPK signaling, may function as tumor
suppressors in breast cancer.
Materials and Methods
Ethics Statement
Informed written consent was obtained from all patients
involved in this study to perform genetic studies and to use
exceeding material for research, and the research project has the
approval of the ethics committee of the Spanish National Cancer
Research Centre (CNIO), named Comite ´d ee ´tica de la investigacio ´n y de
bienestar animal del Instituto de Salud Carlos III.
Samples
Tumor tissue samples were obtained from patients undergoing
surgery for breast cancer from different Hospitals in Spain.
Potential differences regarding ethnicity was not affecting in this
case since all tumors were obtained from Spaniards patients. All
patients belong to high-risk families with at least three members
affected with breast and/or ovarian cancer and at least one of
whom was younger than 50 years when diagnosed. For microarray
analysis we included whole tissue sections from 22 frozen
hereditary breast tumors consisting of 3 BRCA1-mutated, 5
BRCA2 and 14 non-BRCA1/2 (BRCAX) samples, and 14 normal
breast tissues including 3 from BRCA1-mutation carriers, 5 from
BRCA2-mutation carriers. Histopatological features of the tumors
are shown in Table S2, 1 normal breast tissue from contra-lateral
breast of patient with BRCAX tumor, and 5 normal breast tissues.
Normal breast tissues were obtained after breast reduction surgery
from healthy individuals with no family history of breast cancer,
and normal breast tissue from BRCA1/2-mutation carriers were
obtained after prophylactic surgery. The tissue collection used for
validation included 18 paired samples from fresh sporadic breast
tumors and their adjacent normal breast tissue counterparts, RNA
from 6 additional and 4 normal breast tissue samples was also used
for validation. In addition, expression of miR-30c expression was
analyzed by qRT-PCR using RNA from FFPE tumor (12
hereditary and 8 sporadic breast tumors) and 9 breast tissue
samples.
Normal Human Mammary Epithelial Cells (HMEC) (Clonetics)
were used to evaluate miRNA expression comparing with normal
breast tissue. HMEC cells were grown in MEGM, Mammary
Epithelial Growth Medium (Clonetics) supplemented with growth
factors SingleQuots (Clonetics) in absence of FBS.
miRNA Microarray
Total RNA was extracted from primary tumors using Trizol
(Invitrogen). RNA quantity and quality were assessed by
NanoDrop Spectrophotometer (Nanodrop Technologies, Wil-
mington, DE, USA) and Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA), respectively. Microarray
expression profiling was performed using miRCURY LNA
TM
microRNA Array kit (Exiqon A/S, Denmark) according to
manufacturer’s instructions, in a one-color, pair-wise comparison
experimental design. Briefly, 300 ng of total RNA was labeled
with Hy3 fluorescent dye and subsequently hybridized over 16 h
at 56uC onto a miRNA microarray chip (v.11.0– hsa, mmu & rno)
containing 1940 capture probes, in 4 replicates, representing 831
human miRNAs annotated in miRBasev.11 database. A set of 10
synthetic Spike-in RNAs was added to total RNA sample prior to
labeling and later used for quality control. Processed slides were
scanned with Agilent Array scanner (Agilent Technologies), with
the laser set to 635 nm, at Power 80 and PMT 70 setting, and
a scan resolution of 10 mm. Fluorescence intensities on scanned
images were quantified using Feature Extraction software (Agilent
Technologies) using the modified Exiqon protocol. Average values
of the replicate spots were background subtracted and log
transformed and subjected to further analysis. Microarray dataset
is publicly available at GEO database http://www.ncbi.nlm.nih.
gov/geo/info/linking.html under GEO accession number
GSE32922.
Array Data Processing and Statistical Analysis
Raw data were quantile normalized for inter-array variability.
Data was preprocessed to eliminate miRNAs with uniformly low
expression or with low expression variation (SD,0.3) across the
experiments, retaining 466 miRNA genes (306 hsa-miR +160 hsa-
miRPlus). Average linkage hierarchical clustering (Pearson corre-
lation, uncentered metrics) from Gene Cluster and Treeview
(http://rana.stanford.edu/software) algorithms were used to
obtain clustering of the data sets. To determine if there were
genes differentially expressed between tumor and normal breast
tissue, differential expression analysis was performed using t-test
implemented in the POMELO II tool, available in Asterias web
server (http://asterias.bioinfo.cnio.es) [35]. The estimated signif-
icance level were obtained by permutation testing and p-values
were corrected for multiple hypotheses testing using Benjamini &
Hochberg False Discovery Rate (FDR) adjustment [36]. Those
miRNAs in Hereditary Breast Cancer
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differentially expressed.
Quantitative RT-PCR Analysis
Quantitative RT-PCR analysis of miR-30c, miR-100, miR-
125b and miR-320a was performed on independent series of
familial tumors as well as sporadic breast tumor samples and
compared to normal breast tissue samples using miRCURY
LNA
TM microRNA PCR System (Exiqon). Briefly, 10 ng of total
RNA was reverse-transcribed with miRNA specific primers and
Transcriptor Reverse Transcriptase, and the cDNA was used as
a template for the qPCR reaction using miRNA specific LNA
TM
PCR primer and Universal PCR primer. Gene expression levels
were quantified using the ABI Prism Sequence Detection System
7900HT (Applied Biosystems). All experiments were performed in
triplicate and the mean of triplicates was used. Normalization was
done with SNORA66 RNA and 5S rRNA. Relative expression
was calculated using the comparative Ct method.
Pathway Enrichment Analysis
DIANA miRPath pathway enrichment analysis (http://diana.
cslab.ece.ntua.gr/) was used to gain insight into global molecular
networks and canonical pathways related to differentially ex-
pressed miRNAs between normal and tumor samples. DIANA
miRPath is a web-based computational tool developed to identify
molecular pathways potentially altered by the expression of single
or multiple microRNAs. The software performs an enrichment
analysis of multiple microRNA target genes comparing each set of
microRNA targets to all known KEGG pathways. Those pathways
showing p-value ,0.05, were considered significantly enriched
between classes under comparison.
Cell Culture, Constructs and Transfections
The MDA-MB-436 was kindly provided by Dr. K.S Massey-
Brown from Department of Pharmacology and Toxicology,
University of Arizona, Tucson, USA, and was characterized in
previous studies by our group [37]. The MDA-MB-436 cell line
was cultured in RPMI 1640 medium supplemented with 10% FBS
and 100 units/ml of Penicillin G and streptomycin. Cells were split
24 h prior to all transfection assays at a confluence 40–70%. Pre-
miRNA oligonucleotides (pre-miR-30c and scramble control) were
purchased from Ambion (Austin, Texas, USA). For luciferase
reporter assay transfection of oligonucleotides and plasmids was
performed using Lipofectamine 2000 according to the protocols
provided by the manufacturer (Invitrogen, Calsbad, CA). For
proliferation, and KRAS western blot analysis, pre-miRNA
oligonucleotides were transfected to a 50 nM final concentration
using Oligofectamine (Invitrogen).
KRAS-39UTR Luciferase Reporter Assay
39UTR sequence of the KRAS was retrieved through NCBI
nucleotide database. A 300 bp fragment of the 39UTR region of
KRAS gene containing miR-30c binding site, was amplified by
PCR from human genomic DNA, and cloned into a modified
pGL3-Control vector (Promega) at the SacII and EcoRI site,
immediately downstream of the luciferase stop codon. Primer
sequences used to amplify this region were RAS3UTR-F:
59CACGAATTC CACACCCCCACAGAGCTAAC3’ and RA-
S3UTR-R: 59TTCCCGCGGTGTTTGATATGACCAA-
CATTCCT 39. Correct vector construction was verified by direct
sequencing. Dual luciferase assay was carried out by co-
transfecting MDA-MB-436 cells with 25 pmol of pre-miR-30c or
scramble control, along with 500 ng of KRAS 39UTR- firefly
luciferase construct and 7.5 ng of Renilla luciferase vector, using
Lipofectamine 2000 (Invitrogen) per well, according to the
manufacturer’s protocol in a 24-well plate format. Cells were
grown for 48 h, after which luciferase activity was assayed with
Dual-Luciferase Assay System (Promega). Experiments were
performed in triplicate and Renilla luciferase activity was used for
transfection variation normalization.
Detection of KRAS mRNA and Protein Levels
To detect gene expression levels of KRAS, one mg of total RNA
was reverse transcribed using MMLV Reverse Transcriptase
(Invitrogen) and random primers. The cDNAs were subjected to
quantitative RT-PCR assay with the use of labeled probes (Roche
Universal Probe library) and the TaqMan Universal PCR Mix in
an ABI Prism Sequence Detection System 7900HT (Applied
Biosystems) under manufacturer’s recommendations. The PCR
amplification was carried out with 10 min at 95uC, followed by 50
cycles of 15 s at 95uC and 1 min at 60uC, using the oligonucleo-
tides shown in Table S3. ß-actin was used as internal control and
allowed normalization of the samples. All experiments were
analyzed in triplicate.
Western blot analysis was performed using standard procedures
for whole-cell extracts from cell lines. Lysates were prepared using
RIPA buffer (Sigma-Aldrich). Equal amounts of protein lysates
(50–100 mg) were separated by SDS-PAGE on 4–12% pre-casted
gels (Invitrogen), and electrotransferred to nitrocelulose mem-
branes (Wathman) and probed with primary antibody. Antibodies
used were KRAS (F234, Santa Cruz) and GAPDH (CNIO,
Monoclonal Antibodies Unit). Secondary antibody staining was
carried out with anti-mouse HRP IgG (Dakko) and HPR activity
was detected with ECL Detection System (GA Healthcare).
Cell Proliferation Assay
Cell viability was assessed by using 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) assay. MDA-MB-436
cells were transfected in independent experiments with pre-miR-
30c/pre-miR-Scramble oligonucleotides. Cells were incubated in
1 mg/ml MTT Formazan (Sigma-Aldrich) diluted in normal
culture medium at 37uC for 5 h. Cell viability was determined
at 24, 48, 72, 96, 120 or 144 hours after transfection.
Supporting Information
Figure S1 Validation of miRNA expression by qRT-PCR
in hereditary and sporadic tumors. Expression levels of
miR-125b, miR-100, miR-320a in normal breast tissue comparing
with familial tumor samples (FamBC) and sporadic breast cancer
(SpoBC). Differences were estimated by t-test and p values are
shown for each case.
(DOC)
Table S1 Predicted genes within MAPK pathway tar-
geted by deregulated miRNAs in hereditary breast
cancer tumors.
(DOC)
Table S2 Histopathological data from hereditary breast
tumors.
(DOC)
Table S3 Primers used for measuring KRAS expression
by quantitative RT-PCR (used with Universal ProbeLi-
brary probe#62, Roche).
(DOC)
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